🔴 Exclusive webinar: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Saniona AB (SANION)

Stockholm
Currency in SEK
2.85
-0.14(-4.69%)
Real-time Data
SANION Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
2.762.95
52 wk Range
1.746.73
Key Statistics
Edit
Prev. Close
2.99
Open
2.94
Day's Range
2.76-2.95
52 wk Range
1.74-6.73
Volume
316,680
Average Volume (3m)
518,552
1-Year Change
-31.12%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SANION Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Saniona AB Company Profile

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome. It also develops SAN711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of absence seizures; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; and SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures. In addition, the company is developing SAN2355 to treat refractory focal onset seizures; SAN2465 to treat major depressive disorder; and other programs to treat epilepsy, Alzheimer’s, schizophrenia, and migraine. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identigy and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer’s disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Compare SANION to Peers and Sector

Metrics to compare
SANION
Peers
Sector
Relationship
P/E Ratio
−4.1x−1.1x−0.6x
PEG Ratio
0.05−0.020.00
Price/Book
48.2x2.2x2.6x
Price / LTM Sales
13.4x5.5x3.2x
Upside (Analyst Target)
100.7%110.7%43.4%
Fair Value Upside
Unlock30.9%6.4%Unlock

FAQ

What Is the Saniona AB (SANION) Stock Price Today?

The Saniona AB stock price today is 2.85

What Stock Exchange Does Saniona AB Trade On?

Saniona AB is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for Saniona AB?

The stock symbol for Saniona AB is "SANION."

What Is the Saniona AB Market Cap?

As of today, Saniona AB market cap is 315.52M.

What is Saniona AB Earnings Per Share?

The Saniona AB EPS is -0.924.

What Is the Next Saniona AB Earnings Date?

Saniona AB will release its next earnings report on Nov 27, 2024.

From a Technical Analysis Perspective, Is SANION a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.